Response Biomedical Q3 FY16: net income $170K, down 77%; diluted EPS $0.02

Key figures from this report

These are the numbers Response Biomedical reported for Q3 FY16, the quarter ended Sep 30, 2016, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.

1. Net income$170K−77% from $729K in Q3 FY1510-Q income statement, on EDGAR
2. Diluted EPS$0.02−71% from $0.07 in Q3 FY1510-Q income statement, on EDGAR
3. Cash and cash equivalents$1.3M−53% from $2.9M in Q3 FY1510-Q balance sheet, on EDGAR